Oncotelic Therapeutics Featured in NetworkNewsAudio Editorial on Pipeline-Driven Valuation in Biotech

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) is featured in a NetworkNewsAudio Audio Press Release titled “When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech”, which highlights how late-stage drug development assets increasingly drive valuation in the biopharma sector. The editorial, supported by analysis from McKinsey & Company, notes that companies tend to realize the majority of value creation as products approach commercialization, reflecting reduced risk and clearer revenue visibility, a trend directly relevant to Oncotelic’s oncology-focused pipeline and strategic development approach.

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications. The company’s pipeline includes late-stage therapeutic candidates that align with the industry trend where value creation accelerates as products near commercialization. This dynamic is supported by McKinsey’s analysis, which shows that the majority of value in biotech is unlocked during late-stage development and regulatory approval phases.

In addition to its directly owned pipeline, Oncotelic benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. The company also leverages its proprietary AI-enabled PDAOAI platform to support research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration. Beyond internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that further strengthens Oncotelic’s position in oncology and rare disease therapeutics.

The editorial underscores that for investors, the key takeaway is that Oncotelic’s focus on late-stage assets positions it to capture value as its pipeline matures. The company’s ability to leverage its AI platform and extensive patent portfolio further differentiates it in a competitive landscape. As the biopharma industry continues to emphasize risk-adjusted returns, Oncotelic’s strategy of advancing candidates toward commercialization aligns with broader market trends that reward reduced clinical risk and clearer revenue potential. The full editorial is available at https://nnw.fm/42BlH.

For more information about Oncotelic Therapeutics, visit the company’s newsroom at https://nnw.fm/OTLC.